News

From Approval to Treatment, the History of Ipilimumab


 

In conjunction with the Food and Drug Administration's impending approval of another drug for melanoma treatment, vemurafenib, we present this look on the late-stage melanoma drug ipilimumab, how it was approved and the response that followed.

<a href="http://storify.com/ciminosteve/ipilimumab" target="_blank">View "Melanoma Treatment With Ipilimumab (Yervoy)" on Storify</a>

Recommended Reading

Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma
MDedge Hematology and Oncology
Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma
MDedge Hematology and Oncology
AAD President Commends FDA on Sunscreen Regulations
MDedge Hematology and Oncology
Melanoma Patients Respond to Combo of BRAF and MEK Inhibitors
MDedge Hematology and Oncology
Cancer-Protective Effects Seen for Type IV Allergies
MDedge Hematology and Oncology
Melanoma Treatment Ipilimumab Approved Europe-Wide
MDedge Hematology and Oncology
Real-Time Monitoring of Melanoma Markers Predicts Relapse
MDedge Hematology and Oncology
Video of the Week: More Melanoma Treatments on the Way?
MDedge Hematology and Oncology
Laser Therapy of Nonmelanoma Cancers Continues to Grow
MDedge Hematology and Oncology
Melanoma Heads Down the Genetic Pathway
MDedge Hematology and Oncology